[go: up one dir, main page]

ATE234625T1 - Glp-1 zusammensetzungen mit verlängerter wirkdauer - Google Patents

Glp-1 zusammensetzungen mit verlängerter wirkdauer

Info

Publication number
ATE234625T1
ATE234625T1 AT95941606T AT95941606T ATE234625T1 AT E234625 T1 ATE234625 T1 AT E234625T1 AT 95941606 T AT95941606 T AT 95941606T AT 95941606 T AT95941606 T AT 95941606T AT E234625 T1 ATE234625 T1 AT E234625T1
Authority
AT
Austria
Prior art keywords
glp
extended
during compositions
compositions
during
Prior art date
Application number
AT95941606T
Other languages
English (en)
Inventor
Ejvind Jensen
Klavs Holger Jorgensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE234625T1 publication Critical patent/ATE234625T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Soft Magnetic Materials (AREA)
  • Compounds Of Iron (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95941606T 1994-12-23 1995-12-21 Glp-1 zusammensetzungen mit verlängerter wirkdauer ATE234625T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK147894 1994-12-23
PCT/DK1995/000516 WO1996020005A1 (en) 1994-12-23 1995-12-21 Protracted glp-1 compositions

Publications (1)

Publication Number Publication Date
ATE234625T1 true ATE234625T1 (de) 2003-04-15

Family

ID=8105257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941606T ATE234625T1 (de) 1994-12-23 1995-12-21 Glp-1 zusammensetzungen mit verlängerter wirkdauer

Country Status (6)

Country Link
EP (1) EP0796106B1 (de)
JP (1) JPH10511365A (de)
AT (1) ATE234625T1 (de)
AU (1) AU4298596A (de)
DE (1) DE69529998D1 (de)
WO (1) WO1996020005A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ATE307603T1 (de) * 1998-12-22 2005-11-15 Lilly Co Eli Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
SI1140148T1 (sl) * 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
EP1849475A1 (de) 1999-06-21 2007-10-31 Eli Lilly & Company Synergistische Verwendung von Thiazolidindionen mit glucagonartigem Peptid-1 und Agonisten davon zur Behandlung von nicht insulinabhängigen Diabetes
EP2067488A1 (de) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albuminfusionsproteine
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003208945B2 (en) 2002-02-20 2008-05-01 Emisphere Technologies, Inc Method for administering GLP-1 molecules
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー/エス 安定化された薬学的ペプチド組成物
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
CN113304250A (zh) 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
ES2442223T3 (es) 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
ES2735533T3 (es) 2004-11-12 2019-12-19 Novo Nordisk As Formulaciones estables de GLP-1
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
CN105921431B (zh) 2016-05-04 2018-02-06 京东方科技集团股份有限公司 一种转印板清洗设备及其清洗方法
EP4360651A3 (de) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1-zusammensetzungen und verwendungen davon
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CA3165355A1 (en) 2020-02-18 2021-07-22 Tommy SANDER Pharmaceutical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498425A1 (de) * 1986-05-05 2005-01-19 The General Hospital Corporation Verwendung von Glucagonähnlichem-Peptid-1 (GLP-1) Derivaten zur Herstellung von pharmazeutischen Zusammensetzungen
JPS63218247A (ja) * 1987-03-06 1988-09-12 Yoshiaki Kawashima 高機能懸濁液
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition

Also Published As

Publication number Publication date
AU4298596A (en) 1996-07-19
JPH10511365A (ja) 1998-11-04
EP0796106B1 (de) 2003-03-19
DE69529998D1 (de) 2003-04-24
EP0796106A1 (de) 1997-09-24
WO1996020005A1 (en) 1996-07-04

Similar Documents

Publication Publication Date Title
ATE234625T1 (de) Glp-1 zusammensetzungen mit verlängerter wirkdauer
FI920523L (fi) Analgetiska kompositioner.
DE69005438D1 (de) Bernsteinsäureimid-Zusammensetzungen.
DE3575070D1 (de) Analgetische zusammensetzungen.
DE3482781D1 (de) Reinigungsmittelzusammensetzungen.
TR26786A (tr) Polivinilpirolidon iceren kompakt deterjan bilesimi.
DE69423670D1 (de) Siloxy-aluminoxan-Zusammensetzungen
DE69419432D1 (de) Bleichmittelzusammensetzungen
DE69109192D1 (de) Detergenszusammensetzungen.
DE69109193D1 (de) Detergenszusammensetzungen.
MA22840A1 (fr) Compositions nettoyantes.
DE69301999D1 (de) Photoresist Zusammensetzung
DE69105462D1 (de) Desinfizierende Zusammensetzung.
FI921491L (fi) Antimalariakompositioner.
DE68924884D1 (de) Tonerzusammensetzungen.
DE3873550D1 (de) Photopolymerisierbare zusammensetzungen.
DE69413612D1 (de) Wasserstoffperoxid-Zusammensetzung
DE69012475D1 (de) Lichtempfindliche Zusammensetzungen.
FI920210L (fi) Isoleringskomposition.
BR9407124A (pt) Composições contendo surfactante
EP0607899A3 (de) Positiv arbeitende Photoresistzusammensetzung.
MX9205264A (es) Composiciones oleosas.
EP0570884A3 (de) Positivarbeitende Resistzusammensetzung.
BE896665A (fr) Compositions antisolaires.
NO912598D0 (no) Hypokalori-matsammensetning.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties